A KRAS mutation is a change in the KRAS gene that locks a key growth-signaling protein in the “on” position, causing cells to multiply uncontrollably. It is one of the most common genetic drivers of cancer, found in roughly 85% of pancreatic cancers, 45% of colorectal cancers, and 30% of lung adenocarcinomas. These mutations are not inherited in most cases. They develop spontaneously in cells during a person’s lifetime, meaning a KRAS mutation in your tumor does not typically raise the cancer risk for your family members.
How the KRAS Protein Normally Works
The KRAS gene tells your cells how to build a protein called K-Ras, which acts like a molecular on/off switch. When a growth signal arrives at the surface of a cell, K-Ras flips on by grabbing a small energy molecule called GTP. In this active state, it passes the message along to the cell’s nucleus: grow, divide, or mature into a specialized cell type. Once the message is delivered, K-Ras converts GTP into a different molecule (GDP), which flips the switch back off. The protein sits quietly until the next signal comes along.
Helper proteins called GAPs speed up this shutdown process, ensuring K-Ras doesn’t stay active longer than needed. The entire cycle, activation followed by quick deactivation, keeps cell growth tightly controlled.
What Goes Wrong in a KRAS Mutation
When the KRAS gene mutates, the resulting protein loses its ability to flip back off. Specifically, the mutation prevents K-Ras from converting GTP to GDP and blocks GAPs from assisting with the shutdown. The protein stays permanently bound to GTP, continuously sending “grow and divide” signals even when no external signal is present.
This constant signaling floods at least three major pathways inside the cell. One drives cell proliferation. Another promotes cell survival and blocks the normal self-destruct program that damaged cells use to eliminate themselves. A third encourages further growth and metabolic changes. Together, these signals push cells toward the uncontrolled division that defines cancer.
Common Mutation Variants and Their Cancer Links
Not all KRAS mutations are identical. They occur at specific spots on the gene, most often at positions called codons 12, 13, and 61. Each variant swaps out one amino acid for another, and the specific swap influences which cancer type is most likely and how the tumor behaves.
- G12D (glycine replaced by aspartic acid): The most common variant in pancreatic cancer (about 42% of KRAS-mutant cases) and colon cancer (about 27%).
- G12V (glycine replaced by valine): The second most common in pancreatic cancer (27%) and the most frequent in rectal cancer (30%).
- G12C (glycine replaced by cysteine): Dominant in lung adenocarcinoma, accounting for roughly 41% of KRAS mutations in that cancer. This variant has been the first to get targeted drugs.
- G13D: Seen in about 17% of colon cancers, less common in other tumor types.
The variant matters because it shapes treatment options. A patient with a G12C mutation in lung cancer has access to therapies that someone with a G12D mutation does not, at least not yet.
How KRAS Mutations Affect Prognosis
Having a KRAS mutation generally signals a more aggressive cancer. In metastatic colorectal cancer, patients with KRAS mutations had a median overall survival of 17 months compared to 21 months for those without the mutation. The mutation roughly doubled the risk of a worse outcome in that study.
One of the biggest clinical consequences is treatment resistance. KRAS mutations make tumors resistant to a widely used class of targeted therapies that block the EGF receptor, a protein on the cell surface that normally activates K-Ras. When K-Ras is permanently stuck in the “on” position, blocking the receptor upstream accomplishes very little. The growth signal keeps firing regardless. This is why oncologists test for KRAS mutations before prescribing these treatments for colorectal cancer. A positive result means those drugs are unlikely to work.
How KRAS Mutations Are Detected
Testing typically starts with a tissue sample, either from a biopsy or from tumor tissue removed during surgery. Labs analyze the DNA using techniques like PCR (which amplifies and reads specific gene segments) or next-generation sequencing, which can scan hundreds of genes at once and identify the exact mutation variant.
When a tissue sample is difficult to obtain, doctors can use a liquid biopsy instead. This is a standard blood draw that captures tiny fragments of tumor DNA circulating in the bloodstream. Because these fragments are present in very low amounts, the lab uses ultra-sensitive methods to detect them. Liquid biopsies are especially useful for monitoring how a tumor’s genetic profile changes over time without repeated surgical procedures.
Targeted Treatments for KRAS Mutations
For decades, KRAS was considered “undruggable” because the protein’s smooth surface offered no obvious place for a drug to latch on. That changed with the G12C variant. The cysteine amino acid in this mutation provided a chemical hook that drug designers could exploit.
Sotorasib became one of the first approved drugs to directly target KRAS G12C. It was initially approved for non-small cell lung cancer, and in January 2025, the FDA approved it in combination with another drug for metastatic colorectal cancer carrying the G12C mutation. These approvals came with a companion diagnostic test to confirm the specific mutation before treatment.
The G12D variant, the most common across all cancers, has been harder to target because it lacks that same chemical hook. Researchers have developed drugs that bind to the mutant protein through different mechanisms. Several are now in early-stage clinical trials for advanced solid tumors, with one candidate showing response rates of 52% in pancreatic cancer and 42% in lung cancer during Phase I/II testing. Multiple pharmaceutical companies are pursuing this target, and additional candidates are entering trials.
Why Tumors Eventually Resist These Drugs
Even when KRAS-targeted drugs work initially, tumors often find ways around them. The most common escape route involves reactivating the same growth-signaling pathway through a different entry point. When the mutant KRAS protein is blocked, cancer cells can compensate by ramping up activity from other members of the same protein family or by increasing signals from receptors on the cell surface that feed into the same pathway.
Think of it like blocking one lane on a highway. Traffic reroutes through alternate lanes to reach the same destination. This is why researchers are testing drug combinations that block multiple points in the signaling chain simultaneously, aiming to cut off the detour routes along with the main road.